Skip to content
2000
Volume 2, Issue 2
  • ISSN: 1573-4048
  • E-ISSN: 1875-6581

Abstract

In the literature, a distinction between patients with secondary recurrent miscarriage (RM), defined as RM after a previous birth, and primary RM with no preceeding birth is often not made. In this review we point out that there are fundamental epidemiological, clinical and paraclinical differences between these two major subsets of RM patients. There are indications that most cases of secondary RM are caused by an abnormal reaction of the adaptive immune system against the fetus or trophoblast whereas primary RM has a more mixed etiology with many cases caused by disturbances in the coagulation pathways or in the innate immune system. These differences in pathogenesis are reflected in the different responses of the two patient subsets to immunotherapy: many primary RM patients benefit from allogeneic lymphocyte immunization whereas most patients with secondary RM benefit from intravenous immunoglobulin. It is important in future case-control studies or trials of therapy clearly to report the main outcome measures separately for patients with primary and secondary RM, respectively.

Loading

Article metrics loading...

/content/journals/cwhr/10.2174/157340406776931089
2006-05-01
2025-09-15
Loading full text...

Full text loading...

/content/journals/cwhr/10.2174/157340406776931089
Loading

  • Article Type:
    Research Article
Keyword(s): Abortion; immunotherapy; recurrent miscarriage
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test